Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases
NCT05181397Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2021
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in interstitial lung disease (ILD), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05181397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181397.